The development of study exit criteria for evaluating antimanic compounds

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Growing need for safer, more economical methods to study treatments for serious mental illness.
• Acute mania patients are a key group for treatment efficacy studies.
• Current methods for assessing antimanic compounds may involve unnecessary risks or be influenced by external factors.

Purpose of the Study:

• To define novel clinical endpoints or "exit" criteria for assessing antimanic compound efficacy.
• To develop a safer, more economical, and less sensitive method for evaluating treatment response.
• To enable unambiguous assessment of antimanic treatment efficacy.

Main Methods:

• Retrospective analysis of 76 manic or mixed episode admissions (DSM-IV criteria).
• Mixed-effects regression model applied to Bech-Rafaelsen Mania Scale data (admission to day 28).
• Empirical Bayes (EB) estimates of trend coefficients calculated using data through day 11 and all available data.

Main Results:

• High correlation (r = .67) between EB estimates of day 28 response and actual day 28 scores using data through day 11.
• Accurate prediction of treatment response categories (full, partial, non-responders) based on early data.
• High concordance between predicted and actual responder status.

Conclusions:

• Early assessment of treatment response in acute mania is feasible.
• Novel "exit" criteria can be defined based on short-term treatment exposure.
• This approach facilitates more efficient and potentially safer clinical trials for antimanic compounds.